New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder London, UK, April 15, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in...

COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors COMPASS Pathways appoints Wayne J Riley MD to its Board of Directors London, UK – 1 April 2021         COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated...

COMPASS Pathways joins the Psychiatry Consortium in a collaboration to accelerate drug discovery in mental health care London, UK - 9 November 2020 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, has...

COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares  COMPASS Pathways announces closing of initial public offering of American Depositary Shares and full exercise of underwriters’ option to purchase additional American Depositary Shares London, UK –...

COMPASS Pathways announces pricing of upsized initial public offering   COMPASS Pathways announces pricing of upsized initial public offering London, UK – September 18, 2020 COMPASS Pathways plc (Nasdaq: CMPS)...